U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4P
Molecular Weight 95.9715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -3

SHOW SMILES / InChI
Structure of PHOSPHATE ION P-32

SMILES

[O-][32P]([O-])([O-])=O

InChI

InChIKey=NBIIXXVUZAFLBC-HOSYLAQJSA-K
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3/i5+1

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 98.9953
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

1959
PubMed

PubMed

TitleDatePubMed
The use of radioactive phosphorus in the diagnosis of thyroid cancer.
1961 Nov
EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
2007 Aug
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:48:17 GMT 2023
Edited
by admin
on Fri Dec 15 18:48:17 GMT 2023
Record UNII
N27ADP50ER
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHOSPHATE ION P-32
Common Name English
Classification Tree Code System Code
NDF-RT N0000000205
Created by admin on Fri Dec 15 18:48:17 GMT 2023 , Edited by admin on Fri Dec 15 18:48:17 GMT 2023
NDF-RT N0000175872
Created by admin on Fri Dec 15 18:48:17 GMT 2023 , Edited by admin on Fri Dec 15 18:48:17 GMT 2023
Code System Code Type Description
PUBCHEM
167704
Created by admin on Fri Dec 15 18:48:17 GMT 2023 , Edited by admin on Fri Dec 15 18:48:17 GMT 2023
PRIMARY
FDA UNII
N27ADP50ER
Created by admin on Fri Dec 15 18:48:17 GMT 2023 , Edited by admin on Fri Dec 15 18:48:17 GMT 2023
PRIMARY
DRUG BANK
DB14573
Created by admin on Fri Dec 15 18:48:17 GMT 2023 , Edited by admin on Fri Dec 15 18:48:17 GMT 2023
PRIMARY
Related Record Type Details
IONIC MOIETY